Infinium Pharmachem Share Price Today | Stock Price & Infinium Pharmachem Share Screener
Track the current Infinium Pharmachem share price and stock price live with TickJournal's free stock screener. Check INFINIUM 52-week high low for the annual price range and momentum. Use the Infinium Pharmachem stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Infinium Pharmachem opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Key Statistics and Valuation Ratios
Infinium Pharmachem Share Price Chart
Track the current stock price of Infinium Pharmachem with an interactive chart. Analyse INFINIUM share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Infinium Pharmachem stock quote in one place.
Infinium Pharmachem Company Profile - Fundamental Screener
Screen Infinium Pharmachem company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for INFINIUM shares across the equity market and its stock price history, plus the wider market trend.
The company is classified under the Healthcare sector and the Pharmaceuticals industry, and it trades under ISIN INE0MRE01011.
Company Details
Classification
Identifiers and Leadership
Infinium Pharmachem Balance Sheet Screener
Screen INFINIUM balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.
For 2026, total assets were ₹175, down from ₹198 in 2025.
Latest statistics put total assets at ₹175 and shareholder funds at ₹121, with a leverage ratio of 0.38.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
Assets |
|||||||
| Total Assets | 175 | 198 | 86 | 71 | 59 | 34 | 22 |
| Current Assets | 110 | 140 | 65 | 51 | 44 | 26 | 18 |
| Fixed Assets | 32 | 24 | 20 | 19 | 4 | 5 | 4 |
Liabilities |
|||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 8 | 10 | 8 | 10 | 14 | 6 | 6 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Shareholders' Equity |
|||||||
| Total Equity | 121 | 125 | 60 | 24 | 14 | 7 | 4 |
| Share Capital | 16 | 16 | 14 | 5 | 1 | 1 | 1 |
| Reserves & Surplus | 106 | 94 | 45 | 18 | 12 | 6 | 3 |
Infinium Pharmachem Income Statement Screener - Profit & Revenue Analysis
Screen Infinium Pharmachem income statement and profit fundamentals. Analyze INFINIUM quarterly results. Infinium Pharmachem reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.
For None-None, revenue was ₹0 and net profit was ₹0.
In that period expenses were ₹0, interest cost ₹0 and tax ₹0. The next period listed, 2026-March, shows revenue of ₹190 and net profit of ₹14.
| Item | None-None | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March |
|---|---|---|---|---|---|---|---|---|
Revenue and Expenses | ||||||||
| Revenue | 0 | 190 | 158 | 137 | 116 | 100 | 71 | 39 |
| Expenses | 0 | 168 | 139 | 117 | 98 | 89 | 66 | 36 |
Operating Costs and Margins | ||||||||
| EBITDA | 0 | 22 | 19 | 20 | 17 | 11 | 6 | 3 |
| Operating Profit % | 0.00% | 11.00% | 11.00% | 14.00% | 14.00% | 10.00% | 7.00% | 6.00% |
| Depreciation | 0 | 3 | 3 | 3 | 1 | 1 | 1 | 1 |
| Interest | 0 | 3 | 4 | 2 | 3 | 2 | 1 | 1 |
Profit and Earnings | ||||||||
| Profit Before Tax | 0 | 18 | 12 | 15 | 13 | 9 | 4 | 1 |
| Tax | 0 | 4 | 4 | 4 | 3 | 2 | 1 | 0 |
| Net Profit | 0 | 14 | 8 | 12 | 10 | 7 | 3 | 1 |
| EPS | 0.00 | 7.80 | 5.60 | 8.12 | 6.82 | 60.07 | 26.80 | 9.19 |
Infinium Pharmachem Cash Flow Screener - Liquidity Fundamentals
Screen INFINIUM cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.
In 2025-March, operating activities used ₹29, and net cash flow was an inflow of ₹23.
Over the same period, investing activities used ₹27 and financing activities provided ₹79.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March |
|---|---|---|---|---|---|---|
Cash from Operations and Investing | ||||||
| Operating Activities | -29 | -13 | 9 | 12 | 7 | 3 |
| Investing Activities | -27 | -4 | -5 | -7 | -5 | -1 |
Financing and Net Cash | ||||||
| Financing Activities | 79 | 23 | -3 | -2 | -1 | -1 |
| Net Cash Flow | 23 | 6 | 1 | 4 | 1 | 1 |
Infinium Pharmachem Shareholding Pattern Screener
See Infinium Pharmachem shareholding pattern with promoter, FII, and DII holdings. Check Infinium Pharmachem promoter holding and ownership changes for INFINIUM on TickJournal, and see how institutional stock price moves affect the market.
In 2026-Mar, promoters held 64.91%, foreign institutions 0.00%, domestic institutions 0.22% and the public 31.96%, spread across 1,061 shareholders.
The shareholder count was 1,061 in 2026-Mar, compared with 958 in 2025-Mar.
| Item | 2026-Mar | 2025-Mar | 2025-Sept | 2024-Mar | 2024-Sept | 2024-Nov | 2023-Feb | 2023-Mar |
|---|---|---|---|---|---|---|---|---|
Promoter Holding | ||||||||
| Promoter Holding | 64.91% | 65.24% | 59.91% | 73.05% | 73.05% | 65.24% | 100.00% | 100.00% |
Institutional Investors | ||||||||
| FII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DII Holding | 0.22% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Government, Public and Others | ||||||||
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 31.96% | 32.00% | 37.21% | 23.85% | 23.97% | 32.05% | 0.00% | 0.00% |
| Other Holding | 2.91% | 2.76% | 2.88% | 3.10% | 2.98% | 2.71% | 0.00% | 0.00% |
| Shareholder Count | 1,061 | 958 | 1,052 | 771 | 947 | 998 | 17 | 17 |
Dividend Yield Screener - Share Price & Share Analysis
Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Infinium Pharmachem. Infinium Pharmachem dividend yield can be compared with peers and other stocks in the market.
Infinium Pharmachem Stock Index Membership - Nifty & Sensex
See which indices include Infinium Pharmachem stock. Check INFINIUM index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.
Complete Index List
Infinium Pharmachem Market Events Screener - Corporate Actions
Get Infinium Pharmachem corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Infinium Pharmachem stock events that may affect INFINIUM share price, along with derivatives, futures and options activity and sector gainers.
9 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated May 29, 2026, with a record date of May 29, 2026.
It is followed by Quarterly Result Announcement dated November 13, 2025 and Quarterly Result Announcement dated August 21, 2025.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-05-29 | 2026-05-29 | Quarterly Result Announcement | NA | 1.43% |
| 2025-11-13 | 2025-11-13 | Quarterly Result Announcement | NA | -1.29% |
| 2025-08-21 | 2025-08-21 | Quarterly Result Announcement | NA | 6.05% |
| 2025-05-28 | 2025-05-28 | Quarterly Result Announcement | NA | 12.70% |
| 2024-11-14 | 2024-11-14 | Quarterly Result Announcement | NA | 2.10% |
| 2024-10-23 | 2024-10-23 | Extraordinary General Meeting | NA | -8.11% |
| 2024-09-28 | 2024-09-28 | Annual General Meeting | NA | 71.56% |
| 2024-07-06 | 2024-07-06 | Extraordinary General Meeting | NA | 2.78% |
| 2023-09-13 | 2023-09-13 | Bonus | 1:1 | -1.11% |
Infinium Pharmachem Competitors Screener - Peer Stocks Comparison
Screen INFINIUM competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.
The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 441,766 | 36.83 | 61,674 | 12.69% | 11,565 | 47.42 |
| Divis Laboratories | 248,970 | 86.00 | 11,067 | 13.95% | 2,568 | 58.71 |
| Torrent Pharmaceuticals | 182,881 | 86.72 | 13,886 | 20.34% | 2,138 | 48.14 |
| Zydus Life Science | 116,209 | 25.96 | 27,658 | 17.64% | 5,026 | 61.81 |
| Cipla | 110,014 | 33.29 | 29,045 | 2.24% | 3,870 | 44.03 |
| Laurus Labs | 107,052 | 98.39 | 6,868 | 22.01% | 890 | 58.00 |
| Dr Reddys Laboratories | 103,400 | 32.77 | 35,059 | 3.90% | 4,158 | 69.59 |
| Mankind Pharma | 103,311 | 50.84 | 14,636 | 14.85% | 1,938 | 64.24 |
| Aurobindo Pharma | 96,692 | 26.41 | 34,145 | 5.56% | 3,503 | 54.69 |
| Lupin | 93,799 | 16.97 | 29,039 | 26.75% | 5,356 | 34.02 |
Infinium Pharmachem Company Announcements - News & Reports Screener
Screen INFINIUM latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.
Frequently Asked Questions
How is the company valued right now?
The P/B ratio is 3.43. Market capitalisation stands at ₹420.74 Cr. The company operates in the Healthcare sector, in the Pharmaceuticals industry, so compare these ratios with its sector peers in the table above.
About This Data
Key statistics were last updated on October 5, 2026. This page covers 7 balance sheet periods, 8 income statement periods, 6 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.